Last reviewed · How we verify

NCT05759676

Efficacy and Safety of Polymer-free Amphilimus-eluting Stent According to the Diabetes

Recruiting now Last updated 4 April 2024
What this trial tests

trial testing Cre8™/Cre8™ EVO drug-eluting stent in Diabetes Mellitus in 1,800 participants. Currently enrolling.

Timeline
9 March 2023
Primary endpoint
31 August 2026
31 December 2026

Quick facts

Lead sponsorKorea University Anam Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,800
Start date9 March 2023
Primary completion31 August 2026
Estimated completion31 December 2026
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Korea University Anam Hospital

Who can join

19 and older, any sex, with Diabetes Mellitus or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Drug-eluting stents (DES) have been found to reduce the rate of stent restenosis compared to bare metal stents (BMS), but the first generation DES caused an increase in stent thrombosis. The second generation DES, including the Cre8Evo stent, has been designed to address these issues. The Cre8Evo stent is made of cobalt chromium and releases the drug amphilimus into the vessel wall, which is quickly absorbed and then lost, creating a BMS-like form. The Cre8Evo stent does not contain polymers and does not induce an inflammatory response. It inhibits cdk2 and RhoA, reducing the proliferation and migration of vascular smooth muscle cells. In diabetic patients, the Cre8Evo stent showed superior results in suppressing late proliferation compared to conventional DES. The Cre8Evo stent has been found to be safe and effective in clinical studies, and it has a superior effect in the clinical course of diabetic patients compared to other stents. The purpose of the study is to evaluate the effectiveness and safety of the Cre8Evo stent in actual clinical practice, specifically comparing outcomes in patients with and without diabetes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Efficacy and safety of polymer-free amphilimus-eluting stent in patients with and without diabetes mellitus: A prospective, multicenter observational study.
    Lim S, Kim JH, Hong SJ, Cha JJ, et al · · 2025 · PMID 41212864 · DOI 10.1371/journal.pone.0336017

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other Korea University Anam Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05759676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing